Louise Thurman
Psychiatry · Oklahoma City, OKNPI 1356377469
Payments from drug & device makers
Across 730 payments — averaging $8433.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1.4M
- Eli Lilly$1.2M
- Janssen Research & Development, LLC$403K
- Eisai Inc.$215K
- Purdue Pharma L.p.$152K
- plus $780K from 20 others
Across 8 payments — averaging $14,715 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Purdue Pharma L.p.$109K
- Pfizer$8K
- Eli Lilly$967
What the payments were for
- Travel & lodging$2,54083%
- Food & beverage$51017%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 327 | $2,029,136 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 21 | $1,410,119 |
| Eli Lilly | 23 | $1,167,597 |
| Janssen Research & Development, LLC | 68 | $402,588 |
| Eisai Inc. | 124 | $214,583 |
| Purdue Pharma L.p. | 9 | $152,176 |
| Teva Pharmaceuticals USA, Inc. | 24 | $146,517 |
| Supernus Pharmaceuticals, Inc. | 19 | $101,111 |
| Ironwood Pharmaceuticals, Inc | 23 | $97,468 |
| Hikma Pharmaceuticals USA | 6 | $93,014 |
| Avanir Pharmaceuticals, Inc. | 23 | $72,531 |
| Astrazeneca AB | 2 | $63,502 |
| Shire North American Group Inc | 8 | $41,908 |
| Biohaven Pharmaceuticals, Inc. | 10 | $36,817 |
| Novartis | 2 | $25,636 |
| Sage Therapeutics, LLC | 8 | $23,878 |
| AstraZeneca | 15 | $20,077 |
| Acadia Pharmaceuticals Inc | 1 | $15,783 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $14,058 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $8,010 |
| Genentech, Inc. | 3 | $5,425 |
| Chiesi USA, Inc. | 1 | $5,000 |
| Sunovion Pharmaceuticals Inc. | 2 | $3,338 |
| H. Lundbeck A S | 1 | $3,010 |
| Pfizer | 1 | $1,752 |
| Mylan Specialty L.p. | 1 | $1,500 |
How this compares
$6,156,533 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 28 | $668 |
| Quetiapine Fumarate | 37 | $659 |
| Lorazepam | 42 | $658 |
| Gabapentin | 18 | $519 |
| Propranolol Hcl | 11 | $417 |
| Atomoxetine Hcl | 11 | $417 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $385 |
| Trazodone Hcl | 17 | $352 |
| Mirtazapine | 19 | $318 |
| Sertraline Hcl | 19 | $217 |
| Escitalopram Oxalate | 21 | $217 |
| Clonazepam | 27 | $207 |
| Zolpidem Tartrate | 20 | $161 |
| Fluoxetine Hcl | 12 | $158 |
| Aripiprazole | 11 | $145 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Oklahoma City
- Veronique SebastianOklahoma City$3.8M
- Marvin PeytonOklahoma City$3.2M
- Willis HollowayOklahoma City$1.4M
- Courtney NixonOklahoma City$1.2M
- Surinder RandhawaOklahoma City$142K
- Adonis Al BotrosOklahoma City$73K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.